View all CPC CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.



Accreditation/ Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Celldex Therapeutics Inc., Genentech, Lilly, Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Pfizer, and Syndax Pharmaceuticals, Inc.


Community Practice Connections™: 16th Annual International Congress on the Future of Breast Cancer®

Release Date: September 29, 2017
Expiration Date: September 29, 2018
Media: Internet - based

 

Activity Overview

The Community Practice Connections™: 16th Annual International Congress on the Future of Breast Cancer® serves as an update on advances in the breast cancer field, with a focus on the clinical implications of breast cancer genetic and phenotypic subtyping. Novel agents, strategies, and improved regimens are changing the future of breast cancer therapy, and these advances and their clinical impact are highlighted throughout the program. Current controversies in the field are also addressed and new data presented, along with information about how to optimally individualize breast cancer therapy. This activity provides a unique opportunity for medical, surgical, and radiation oncologists and other healthcare professionals to increase knowledge, apply new data to practice, and, ultimately, improve patient outcomes.

CME/CE Activity Table of Contents

  • Module A: Novel Therapeutic Strategies for Triple-Negative Breast Cancer, With Joyce O’Shaughnessy, MD
  • Module B: Management of HER2-Driven Breast Cancers, With Sara Hurvitz, MD
  • Module C: Integrating Targeted Therapies Into the Management of Hormone Receptor‒Positive Breast Cancer, With Richard Finn, MD
  • Module D: Utility of Molecular Signatures in Managing Early Breast Cancer, With Adam M. Brufsky, MD, PhD

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a cme/ce certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a cme/ce certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer may also participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Determine testing strategies that can be utilized to facilitate the diagnosis, ability to stratify risk, and identification of predictive markers in the care of patients with breast cancer
  • Apply personalized treatment planning to manage patients with breast cancer based on information obtained from testing strategies
  • Delineate approaches that apply local therapies, such as surgical and radiation therapies, to manage patients with breast cancer
  • Describe key evidence concerning the use of evolving strategies for the care of patients with breast cancer
  • Place recent clinical trial findings in the context of evolving treatment paradigms in the field of breast cancer management
  • Identify patients who may benefit from inclusion in a clinical trial evaluating investigational approaches in the setting of breast cancer

Faculty, Staff, and Planners' Disclosures

Co-Chairs

Joyce O'Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Texas Oncology
Chair, Breast Cancer Research Program
The US Oncology Network
Dallas, TX

Disclosure: Consultant: Arno Therapeutics, AstraZeneca, Celgene, Corcept Therapeutics, Eisai, Genentech, GlaxoSmithKline, Lilly, J&J, Merrimack, Novartis, Pfizer, Roche, Sanofi, Takeda, Medfusion

Sara Hurvitz, MD
Director, Breast Cancer Clinical Research Program
Co-Director, Santa Monica – UCLA Outpatient Hematology/Oncology Practice
Associate Professor of Medicine, Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Santa Monica, CA

Disclosure: Grant/Research Support: Amgen, Bayer, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Pfizer, Roche, BioMarin, Merrimack, OBI Pharma, Puma Biotechnology, Dignitana, Medivation, Lilly, Novartis, OBI Pharma, Other: Lilly, Novartis, OBI Pharma: travel

Faculty

Adam M. Brufsky, MD, PhD
Professor of Medicine
Associate Chief, Division of Hematology/Oncology
Co-Director, Comprehensive Breast Cancer Center
Associate Director, Clinical Investigation
University of Pittsburgh School of Medicine
Pittsburgh, PA

Disclosure: Consultant: Novartis, Roche, Eisai, Celgene, Lilly, Pfizer, Agendia, Genomic Health, NanoString Technologies, Biotheranostics

Richard S. Finn, MD
Associate Professor of Medicine
Department of Medicine, Division of Hematology/ Oncology
David Geffen School of Medicine
University of California, Los Angeles
Santa Monica, CA

Disclosure: Consultant: Pfizer, Bayer, Novartis, Bristol-Myers Squibb, Eisai

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

CME/CE Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
info@gotoper.com

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise




Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
2627282930
Filter By